ANOTHER RECORD-SETTING QUARTER FOR ZINZINO - THE COMPANY IS INCREASING THE FORECAST FOR 2020
Strong growth in Central Europe combined with good development on most other markets contributed to total revenues increasing by 53% to SEK 274.3 (179.5) million during the second quarter. During the quarter, Zinzino continued to adapt and optimize operations to maintain the good sales growth during the pandemic outbreak. The outcome has been favorable, which means that the company adjusts the sales forecast for 2020 by SEK 100 million to SEK 1,100 million.
To achieve more efficient shipments to Central and Eastern Europe, Zinzino opened a new logistics center in Poland during the quarter. In the UK, sales have started for the new, local subsidiary and in Asia, work continued on the acquisition of VMA Life, and the opening of Zinzino in Hong Kong is getting closer. In early July 2020, Zinzino launched a new version of www.zinzinotest.com, the site where over 500,000 blood test analyses have been made - now with updated functionality, design and layout.
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12,
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email:
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 08.00 the 28th of August 2020.
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North Growth Market.